VX-478 HIV protease inhibitor data

Partner Glaxo Wellcome reported Phase I results with escalating doses of the Cambridge, Mass., company's drug in 18 HIV-positive people, showing that oral bioavailability was greater than 70 percent, with no adverse effects or laboratory abnormalities.

Doses tested were 150, 300, 600, 900 and 1200 mg. Average concentrations in blood at 8 and 12 hours after either 900 or 1200 mg were more than 20 times the level anticipated to provide antiviral activity (IC90). ...